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MaBACKGROUND Pro-substance P (ProSP) is a stable surrogate marker for labile substance P, which has pro-
inﬂammatory effects, increases platelet aggregation and clot strength, and reduces ﬁbrinolysis.
OBJECTIVES This study assessed whether ProSP was associated with poor prognosis after acute myocardial
infarction (AMI) to identify novel pathophysiological mechanisms.
METHODS ProSP was measured in 1,148 AMI patients (825 men, mean age 66.2  12.8 years). Endpoints were major
adverse cardiac events (composite of death, reinfarction, and heart failure [HF] hospitalization), death/reinfarction,
and death/HF. GRACE (Global Registry of Acute Coronary Events) scores were compared with ProSP for death and/or
reinfarction at 6 months.
RESULTS During 2-year follow-up, there were 140 deaths, 112 HF hospitalizations, and 149 re-AMI. ProSP levels
were highest on the ﬁrst 2 days after admission and related to estimated glomerular ﬁltration rate, age, history of
diabetes, ischemic heart disease or hypertension, Killip class, left ventricular wall motion index, and sex. Multivariate
Cox regression models showed ProSP level was a predictor of major adverse events (hazard ratio [HR]: 1.30; 95%
conﬁdence interval [CI]: 1.10 to 1.54; p < 0.002), death and/or AMI (HR: 1.42; 95% CI: 1.20 to 1.68; p < 0.0005),
death and/or HF (HR: 1.38; 95% CI: 1.14 to 1.67; p < 0.001). ProSP levels with GRACE scores were independent
predictors of 6-month death and/or reinfarction (p < 0.0005 for both). ProSP-adjusted GRACE scores reclassiﬁed
patients signiﬁcantly (overall category-free net reclassiﬁcation improvement of 31.6 (95% CI: 14.3 to 49.0;
p < 0.0005) mainly by down-classifying those without endpoints.
CONCLUSIONS ProSP levels post-AMI are prognostic for death, recurrent AMI, or HF, and they improve risk prediction
of GRACE scores, predominantly by down-classifying risk in those without events. (J Am Coll Cardiol 2014;64:1698–707)
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AB BR E V I A T I O N S
AND ACRONYM S
AMI = acute myocardial
infarction
AUC = area under the curve
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1699antiplatelet agents (such as aspirin and adenosine
diphosphate receptor antagonists), and aldosterone
antagonists. Although patient prognosis has im-
proved, there remains a need to identify new pathways
that may further improve outcomes after infarction.SEE PAGE 1708 CI = conﬁdence interval(s)
eGFR = estimated glomerular
ﬁltration rate
HF = heart failure
HR = hazard ratio(s)
MACE = major adverse cardiac
event(s)
NK = neurokinin(s)
NT-proBNP = N-terminal
pro-B-type natriuretic peptide
ProSP = Pro-substance P
SP = substance P
STEMI = ST-segment elevation
myocardial infarctionSubstance P (SP) and the neurokinins (NK) belong
to the tachykinin family and are widely distributed in
the central and peripheral nervous system (1).
Although levels of SP are low in the myocardium, SP
still can affect the heart via its role in nociception,
inﬂammation, plasma extravasation, platelet and
leukocyte aggregation in post-capillary venules, and
leukocyte chemotactic migration through vessel walls
(1). As for NK receptors, they are mainly present in
coronary vessels and intracardiac ganglia, but not on
the ventricular or atrial myocardium (2). One direct
action on the NK1 receptor in coronary arteries may
be nitric oxide–mediated vasodilation (1), although
this effect may be impaired in patients with coronary
artery disease (3), leading to a dominant NK2-
mediated vasoconstriction. Both SP and neurokinin
A are negatively inotropic and chronotropic, acting
via cholinergic neurons (2), whereas NK1 antagonists
improve inotropy and lusitropy in rat AMI models. SP
attenuates the positive inotropic effect of norepi-
nephrine (4) and, via the NK1 receptor, has been
implicated in myocardial stunning post-AMI in
guinea pigs (5).
SP is also expressed in platelets, where it has a pro-
aggregatory effect (6). Furthermore, NK1 receptor
inhibition reduces thrombus formation. Administra-
tion of an NK1 receptor antagonist reduced ﬁbrinous
adhesion formation and increased tissue plasmin-
ogen activator messenger ribonucleic acid and activ-
ity, suggesting that SP has a role in ﬁbrinolysis (7).
Also, SP strengthens clots formed in blood, an effect
that may be mediated via leucocytes, the magnitude
of which depends on full-length or truncated NK1
receptor isoform expression (8).
Myocardial (9) and pulmonary (10) SP has been
observed to be increased in animal models of
AMI, although investigations in humans have been
hampered by the very short half-life of SP (12 min)
(11), so there are no large studies examining the role of
SP in AMI. The recent development of an assay
for stable pro-tachykinin A (Pro-substance P [ProSP]),
a surrogate for labile SP (12), has enabled studies on
the role of this tachykinin system in human disease.
We therefore investigated the potential role of SP
in AMI by measuring ProSP and studying its associa-
tion with major adverse cardiac events (MACE) such as
death, heart failure (HF), or reinfarction.METHODS
STUDY POPULATION. We studied 1,148 ST-
segment elevation myocardial infarction
(STEMI) and non-STEMI patients admitted to
University Hospitals of Leicester National
Health Service trust between August 1, 2004
and April 30, 2007. This observational cohort
study complied with the Declaration of
Helsinki and was approved by the local ethics
committee; patients gave written informed
consent. AMI was diagnosed if a patient had a
cardiac troponin I level above the 99th
percentile with $1 of the following: chest
pain lasting >20 min or diagnostic serial elec-
trocardiographic changes consisting of new
pathological Q waves or ST-segment and
T-wave changes (13). Patients with known
malignancy, renal replacement therapy, or
surgery in the previous month were excluded.
Estimated glomerular ﬁltration rate (eGFR) was
calculated from the simpliﬁed Modiﬁcation of Diet in
Renal Disease formula (14). All patients received
standard medical treatment and revascularization at
the discretion of the attending physician.
PLASMA SAMPLES. Blood samples (anticoagulated
with ethylenediaminetetraacetic acid and aprotinin)
were drawn after 15 min bed rest, immediately
after diagnosis, and within 36 h of symptom onset.
Plasma was stored at –80C until assayed in a single
batch for blinded determination of plasma ProSP
and N-terminal pro-B-type natriuretic peptide (NT-
proBNP).
ECHOCARDIOGRAPHY. Transthoracic echocardiog-
raphy was performed in 895 patients (77.9%) during
index admission, using either a Sonos 5500 or IE 33
instrument (Philips Medical Systems, Reigate, United
Kingdom). A 16-segment left ventricular wall motion
index score was performed on the basis of the Amer-
ican Society of Echocardiography method (15). In
suitable patients, left ventricular ejection fraction was
calculated using the biplane method of disks formula.
Left ventricular systolic dysfunction was deﬁned as
either a left ventricular ejection fraction <40% or a
left ventricular wall motion index >1.8.
GRACE (GLOBAL REGISTRY OF ACUTE CORONARY
EVENTS) SCORING. On the basis of an international
observational database of acute coronary syndrome
patients, GRACE scores can be calculated on initial
presentation to predict in-hospital mortality (16) or
for 6-month MACE, deﬁned as death and/or rein-
farction (17). We used GRACE scores on discharge
for comparison with later outcomes.
TABLE 1 Characteristics of Acute Myocardial Infarction Patients According to ProSP Quartiles on Admission
All
(n ¼ 1,148)
ProSP Quartiles
p Value
1
<52.0
pmol/l
(n ¼ 288)
2
52.0–65.19
pmol/l
(n ¼ 286)
3
65.19–89.1
pmol/l
(n ¼ 288)
4
>89.1
pmol/l
(n ¼ 286)
ProSP, pmol/l 77.2  55.7 42.2  7.43 58.4  4.0 75.6  7.1 132.9  87.4 <0.0005
NT-proBNP, pmol/l 1,849  2,108 891.3  1,062 1,339  1,641 1,874  2,030 3,300  2,569 <0.0005
Demographics
Age, yrs 66.2  12.8 58.3  11.2 63.1  11.0 68.1  11.9 75.4  10.3 <0.0005
Male 825 (72) 235 (82) 214 (75) 208 (72) 168 (59) <0.0005
ST-segment elevation AMI 545 (47) 144 (50) 132 (46) 149 (52) 120 (42) NS
Previous history
IHD 379 (33) 67 (23) 80 (28) 91 (32) 141 (49) <0.0005
Heart failure 46 (4) 3 (1) 8 (3) 10 (3) 19 (7) <0.003
Hypertension 596 (52) 125 (44) 134 (47) 152 (53) 185 (65) <0.0005
Diabetes mellitus 266 (23) 53 (18) 71 (25) 61 (21) 81 (28) 0.032
Killip class >1 426 (40) 61 (24) 92 (35) 121 (45) 152 (56) <0.0005
Glucose, mmol/l 8.9  4.2 8.5  3.9 8.7  3.9 8.4  3.5 9.9  5.4 <0.007
Troponin I, ng/ml 13.1  25.8 13.2  26.7 12.0  24.4 15.0  27.9 12.1  24.2 NS
eGFR, ml/min/1.73 m2 65.6  20.1 77.9  17.7 71.4  15.5 64.4  16.6 48.9  17.9 <0.0005
Risk markers on discharge
Echocardiographic LVSD, n ¼ 893
LV wall motion index 1.47  0.42 1.38  0.37 1.46  0.42 1.46  0.41 1.60  0.43 <0.0005
LV ejection fraction 42.1  14.5 44.8  13.8 43.8  14.3 41.4  13.8 38.3  15.2 <0.0005
GRACE score 120.0  32.7 99.7  26.6 109.6  26.9 125.6  28.4 144.5  29.9 <0.0005
Treatment
Aspirin 963 (84) 255 (89) 255 (89) 238 (83) 215 (75) <0.0005
Beta-blocker 920 (80) 256 (89) 238 (83) 230 (80) 196 (69) <0.0005
ACE inhibitor or ARB 940 (82) 249 (87) 234 (82) 245 (85) 212 (74) <0.0005
Statin 1,002 (87) 270 (94) 258 (90) 260 (90) 214 (75) <0.0005
Loop diuretic agent 289 (25) 39 (14) 59 (21) 69 (24) 122 (43) <0.0005
Revascularization 343 (30) 95 (33) 99 (35) 79 (27) 70 (24) 0.027
Endpoints, 2 yrs
MACE 324 (28) 45 (16) 53 (19) 77 (27) 149 (52) <0.0005
Death 140 (12) 11 (4) 11 (4) 31 (11) 87 (30) <0.0005
Nonfatal MACE 230 (20) 41 (14) 46 (16) 56 (19) 87 (30) <0.0005
Heart failure 112 (10) 13 (5) 19 (7) 28 (10) 52 (18) <0.0005
Reinfarction 149 (13) 29 (10) 35 (12) 33 (11) 52 (18) 0.021
Values are mean  SD or n (%). The p values are quoted for the Kruskal-Wallis or chi-square tests for continuous or categorical variables, respectively.
ACE ¼ angiotensin-converting enzyme; AMI ¼ acute myocardial infarction; ARB ¼ angiotensin II receptor blocker; eGFR ¼ estimated glomerular ﬁltration rate; GRACE ¼
Global Registry of Acute Coronary Events; IHD ¼ ischemic heart disease; LV ¼ left ventricular; LVSD ¼ left ventricular systolic dysfunction; MACE ¼ major adverse cardiac
event(s); NS ¼ not signiﬁcant; NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; ProSP ¼ pro-substance P.
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1700BIOMARKER ASSAYS. The NT-proBNP assay was
on the basis of a noncompetitive assay as previously
published (18). Troponin I was measured using
the Centaur cTnI Ultra immunoassay (Siemens
Healthcare Diagnostics, Munich, Germany), which
has a coefﬁcient of variation of 10% at 0.03 mg/l with a
99th percentile of 0.04 mg/l. An assay for stable ProSP
has been previously reported in detail (12) and was
modiﬁed as follows: a mouse monoclonal anti-ProSP
antibody (against amino acid sequence 21 to 36 of
ProSP) was used to coat polystyrene tubes. Polyclonal
antibodies against amino acids 3 to 22 of the ProSP
sequence were labelled with methyl-acridinium esterand served as the detector antibody. Standards
(ProSP peptide; amino acids 1 to 37 of ProSP) and
samples (50 ml) were incubated in tubes with the de-
tector antibody (200 ml). After equilibration, tubes
were washed and bound chemiluminescence was
detected with a luminometer LB952T/16 (Berthold,
Wildbad, Germany). The lower detection limit of the
immunoassay was 4.4 pmol/l.
ENDPOINTS. The primary composite endpoint was
MACE, deﬁned as all-cause mortality, HF hospitali-
zation, or recurrent AMI within 2 years of the index
event. Hospitalization for HF was deﬁned as a hos-
pital readmission for which HF was the primary
TABLE 2 General Linear Model Showing Independent Predictors of ProSP Levels
Coefﬁcient
Standard
Error
Lower
95% CI
Upper
95% CI p Value
eGFR –0.00345 0.00045 –0.004 –0.003 <0.001
Age 0.003272 0.000548 0.002 0.004 <0.001
Killip class >1 0.045352 0.012334 0.021 0.070 <0.001
Male 0.011859 0.013149 –0.014 0.038 NS
History of IHD 0.015876 0.012434 –0.008 0.040 NS
History of hypertension –0.00233 0.011583 –0.025 0.020 NS
History of diabetes 0.024257 0.014706 –0.005 0.053 NS
Diastolic BP –0.00036 0.000359 –0.001 0.000 NS
Heart rate 0.00021 0.000231 0.000 0.001 NS
LVSD 0.004572 0.012434 –0.020 0.029 NS
Coefﬁcients reported for 2,000 bootstrapped samples.
BP ¼ blood pressure; CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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FIGURE 1 Proﬁle of Plasma ProSP Over 5 Days After AMI
The proﬁle includes those with post-AMI MACE at 2 years
(salmon) or those without MACE at 2 years (periwinkle).
AMI ¼ acute myocardial infarction; MACE ¼ major adverse
cardiac event(s); ProSP ¼ pro-substance P.
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1701reason requiring treatment with high-dose diuretic
agents, inotropes, or intravenous nitrate. Reinfarc-
tion was determined using the universal deﬁnition
for MI (13). Other secondary composite endpoints
were death and/or reinfarction and death and/or HF
readmission. The endpoint of death and/or recurrent
AMI at 6 months was used in analyses involving the
GRACE score as this time point was used in devel-
oping the risk score. Endpoints were obtained by
reviewing the local hospital databases and patient
records, the Ofﬁce of National Statistics Registry, and
phone calls to patients. We achieved 100% follow-up.
STATISTICAL ANALYSIS. Statistical analyses were
performed on SPSS (version 20, IBM Corp., Armonk,
New York) and Stata (version 12.1, StataCorp LP, Col-
lege Station, Texas). Biomarker levels were log10
transformed and hazard ratios for these refer to 1 SD
increment of the log10 transformed biomarker. GRACE
scores were used as the original scores. Nonparametric
tests were employed for data analysis (chi-squared
test, Kruskal-Wallis test, and Spearman [rs] correla-
tions). Independent predictors of ProSP levels were
assessed using general linear models, with coefﬁcients
and p values reported for 2,000 bootstrap samples. To
assess prognostic value of biomarkers, a “base” model
was generated using Cox survival analysis, which
included variables that were signiﬁcantly (p < 0.10)
associated with any of the study endpoints on uni-
variate analysis (age, sex, previous history of ischemic
heart disease, hypertension or diabetes, Killip class,
eGFR, and biomarkers [log troponin I and log NT-
proBNP]). ProSP was added to this base model to
evaluate its added prognostic value. A second
“comparative” Cox model was used to assess the
relative prognostic power of NT-proBNP, ProSP, and
the GRACE score. To demonstrate independence from
clinical variables and NT-proBNP or the GRACE score
with and without NT-proBNP, the added value of
ProSPwas evaluated on the basis of the likelihood ratio
chi-square test for nested regression models. The
additional prognostic value of ProSP in the base and
comparative Cox models was further evaluated by
reclassiﬁcation analysis with calculation of category-
free net reclassiﬁcation improvement as described by
Pencina et al. (19). We constructed classiﬁcation trees
using chi-square Automatic Interaction Detection
(analysis performed using SPSS), which detects which
biomarker has the strongest interaction with the
dependent variable in stepwise analysis.
RESULTS
PATIENT CHARACTERISTICS. The characteristics of
the study population are shown in Table 1, accordingto ProSP quartiles. Patients with higher ProSP levels
were older, female, and more likely to have histories
of hypertension, ischemic heart disease, diabetes, or
HF. Higher ProSP levels also were associated with
higher GRACE scores, NT-proBNP, and glucose levels,
and lower ejection fractions and eGFR.
CORRELATION ANALYSIS. Spearman correlation
analysis (rs) showed ProSP was signiﬁcantly correlated
to age (0.521), eGFR (–0.555), diastolic blood pressure
(–0.178), NT-proBNP (0.428), wall motion score index
TABLE 3 Cox Regression Analysis for MACE at 2 Years Post-AMI
Univariable,
HR (95% CI) p Value
Multivariable
Model 1, HR (95% CI) p Value
Multivariable
Model 2, HR (95% CI) p Value
Age, yrs 1.05 (1.04–1.06) 0.001 1.03 (1.01–1.04) 0.001 1.02 (1.01–1.04) 0.002
Male 0.62 (0.50–0.78) 0.001 1.09 (0.83–1.45) NS 1.07 (0.81–1.42) NS
ST-segment elevation 1.09 (0.88–1.36) NS 1.35 (0.98–1.85) NS 1.28 (0.93–1.76) 0.035
Killip class >1 2.65 (2.10–3.34) 0.001 1.60 (1.22–2.11) 0.001 1.56 (1.18–2.06) 0.002
eGFR, ml/min/1.73 m2 0.97 (0.96–0.98) 0.001 0.99 (0.98–0.99) 0.002 0.99 (0.98–1.00) NS
Heart rate, beats/min 1.01 (1.01–1.01) 0.001 1.01 (1.00–1.01) NS 1.00 (0.99–1.00) NS
Systolic BP, mm Hg 0.99 (0.99–1.00) 0.043 0.99 (0.99–1.00) NS 0.99 (0.99–1.00) NS
Past history
IHD disease 1.54 (1.23–1.91) 0.001 1.01 (0.76–1.34) NS 0.97 (0.73–1.29) NS
Hypertension 1.64 (1.31–2.06) 0.001 1.16 (0.87–1.55) NS 1.17 (0.87–1.55) NS
Diabetes 1.55 (1.22–1.96) 0.001 1.32 (0.99–1.74) NS 1.31 (0.99–1.74) NS
Biomarkers
Log troponin, mg/l 1.12 (0.99–1.26) 0.07 1.08 (0.93–1.25) NS 1.08 (0.93–1.25) NS
Log NT-proBNP, pmol/l 1.93 (1.65–2.25) 0.001 1.28 (1.04–1.57) 0.018 1.21 (0.98–1.48) NS
Log ProSP, pmol/l 1.81(1.65–1.99) 0.001 Excluded 1.30 (1.10–1.54) 0.002
Log Likelihood chi-square 152.39 171.30 0.0001*
Multivariable analysis results in model 1 included variables and biomarkers (except ProSP) that were signiﬁcant on univariable analysis. Multivariable Model 2 used the variables
in model 1 with the addition of ProSP as a continuous variable. *This p value is for the increment in log likelihood chi-square for models.
HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.
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1702(0.173), and heart rate (0.172) (all p < 0.0005). ProSP
was not correlated to troponin or peak creatine kinase
levels. A general linear model with 2,000 bootstrap
samples showed eGFR, age, and Killip class > 1 as in-
dependent predictors of ProSP level (Table 2).100
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FIGURE 2 Kaplan-Meier Plots for the Endpoint of MACE
According to ProSP Quartiles
Event-free survival according to ProSP quartiles are plotted, with
follow-up over 2 years. Patients in the highest ProSP quartiles
have the highest rates of death, heart failure, and reinfarction
(MACE). Abbreviations as in Figure 1.DAY CURVES FOR PROSP. Sequential plasma sam-
pling over 5 days was available for 110 patients, of
whom 29 had a MACE within 2 years. Figure 1 dem-
onstrates the plasma proﬁle along with a general
linear model with repeated measures that show sig-
niﬁcant changes in ProSP over time (p < 0.001) and
higher levels in those with MACE (p < 0.03). In post-
hoc testing, ProSP levels on day 1 were higher than on
days 3, 4, or 5 (p < 0.001, 0.004, and 0.002, respec-
tively; Bonferroni corrected for multiple compari-
sons). ProSP levels on days 1 and 2 were similar. There
was no statistically signiﬁcant interaction of the time
proﬁle of ProSP with MACE.
SURVIVAL ANALYSIS. During 2-year follow-up, pa-
tients with elevated ProSP levels (log10 transformed
and standardized by 1 SD) had more MACE, deaths,
and rehospitalizations with HF or reinfarction
(Table 1). Table 3 shows the univariate hazard ratios
(HR) of various factors that affected MACE. In multi-
variate analysis for predicting 2-year MACE, signiﬁ-
cant independent predictors included age, Killip class
>1, eGFR, and NT-proBNP. Addition of ProSP to the
model (model 2 in Table 3) showed ProSP had an in-
dependent predictive value (HR: 1.30; 95% conﬁ-
dence interval [95% CI]: 1.10 to 1.54; p < 0.002), and
the added value of ProSP as evaluated by the likeli-
hood ratio chi-square test for nested regression
models was p < 0.0001. Kaplan-Meier survival anal-
ysis visualizes the MACE rates in ProSP quartiles
(Figure 2), showing quartile 4 was signiﬁcantly
different from all other quartiles (p < 0.0005, log rank
TABLE 4 Cox Regression Analysis for Death and/or Reinfarction at 2 Years Post-AMI
Univariable,
HR (95% CI) p Value
Multivariable Model 1,
HR (95% CI) p Value
Multivariable Model 2,
HR (95% CI) p Value
Age, yrs 1.05 (1.04–1.06) 0.001 1.03 (1.01–1.04) 0.003 1.02 (1.01–1.04) 0.01
Male 0.66 (0.51–0.85) 0.001 1.15 (0.83–1.58) NS 1.11 (0.81–1.52) NS
ST-segment elevation 1.03 (0.81–1.32) NS 1.21 (0.84–1.75) NS 1.14 (0.79–1.64) NS
Killip class >1 2.07 (1.61–2.67) 0.001 1.19 (0.87–1.62) NS 1.14 (0.83–1.56) NS
eGFR, ml/min/1.73 m2 0.97 (0.96–0.98) 0.001 0.99 (0.98–0.99) 0.006 1.00 (0.99–1.01) NS
Heart rate, beats/min 1.01 (1.00–1.01) 0.001 1.00 (0.99–1.00) NS 1.00 (0.99–1.00) NS
Systolic BP, mm Hg 1.00 (0.99–1.00) NS 1.00 (0.99–1.00) NS 1.00 (0.99–1.00) NS
Past history
IHD 1.62 (1.27–2.07) 0.001 1.20 (0.87–1.65) NS 1.15 (0.83–1.59) NS
Hypertension 1.56 (1.21–1.99) 0.001 1.05 (0.77–1.45) NS 1.06 (0.77–1.47) NS
Diabetes 1.54 (1.18–2.00) 0.001 1.28 (0.93–1.75) NS 1.25 (0.91–1.71) NS
Biomarkers
Log troponin, mg/l 1.06 (0.92–1.21) NS 1.06 (0.89–1.26) NS 1.06 (0.90–1.25) NS
Log NT-proBNP, pmol/l 1.83 (1.54–2.17) 0.001 1.29 (1.02–1.63) 0.032 1.19 (0.95–1.50) NS
Log ProSP, pmol/l 1.76 (1.60–1.94) 0.001 Excluded 1.42 (1.20–1.68) 0.0005
Log likelihood chi-square 93.45 119.72 0.0001*
Multivariable analysis results are reported for model 1, which included variables and biomarkers (except ProSP) that were signiﬁcant on univariable analysis. Multivariable model
2 used the variables in model 1 with the addition of ProSP. *This p value is for the increment in log likelihood chi-square for models.
Abbreviations as in Tables 1, 2, and 3.
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1703test [Mantel-Cox]), and quartile 3 was signiﬁcantly
different from quartiles 4 (p < 0.0005), 2 (p < 0.022),
and 1 (p < 0.001).
There was no signiﬁcant beneﬁt with the inclusion
of glucose in Cox survival models for MACE (HR: 1.11;
95% CI: 0.97 to 1.26; p ¼ NS), but there was for ProSP
(HR: 1.24; 95% CI: 1.03 to 1.49; p ¼ 0.02). Inclusion of
white cell count in survival models for MACE showedTABLE 5 Cox Regression Analysis for Death and/or HF at 2 Years Pos
Univariable,
HR (95% CI) p Value
Multiv
H
Age, yrs 1.07 (1.06–1.09) 0.001 1.0
Male 0.51 (0.39–0.66) 0.001 1.0
ST-segment elevation 0.99 (0.77–1.29) NS 1.1
Killip class >1 3.71 (2.76–4.99) 0.001 2.0
eGFR, ml/min/1.73 m2 0.96 (0.95–0.97) 0.001 0.9
Heart rate, beats/min- 1.01 (1.01–1.02) 0.001 1.00
Systolic BP, mm Hg 0.99 (0.98–0.99) 0.004 0.9
Past history
IHD 1.59 (1.22–2.06) 0.001 0.8
Hypertension 1.70 (1.30–2.23) 0.001 1.0
Diabetes 1.58 (1.19–2.09) 0.001 1.4
Biomarkers
Log troponin, mg/l 1.16 (1.00–1.33) 0.044 1.0
Log NT-proBNP, pmol/l 3.21 (2.57–4.02) 0.001 1.6
Log ProSP, pmol/l 2.07 (1.87–2.29) 0.001
Log likelihood chi-square
Multivariable analysis results are reported for model 1, which included variables and bioma
2 used the variables in model 1 with the addition of ProSP. *This p value is for the incre
HF ¼ heart failure; other abbreviations as in Tables 1, 2, and 3.no effect either (HR: 0.98; 95% CI: 0.95 to 1.01; p ¼
NS) compared with ProSP, which did (HR: 1.27; 95%
CI: 1.06 to 1.53; p ¼ 0.01).
In other models for prediction of the secondary
composite endpoints of death and/or recurrent AMI
(Table 4) and death and/or HF readmission (Table 5),
ProSP remained an independent predictor (p < 0.0005
and p < 0.001, respectively) of these endpoints.t-AMI
ariable Model 1,
R (95% CI) p Value
Multivariable Model 2,
HR (95% CI) p Value
4 (1.02–1.06) 0.001 1.04 (1.02–1.06) 0.001
1 (0.72–1.41) NS 0.98 (0.70–1.37) NS
3 (0.76–1.67) NS 1.06 (0.72–1.57) NS
2 (1.42–2.86) 0.001 1.95 (1.37–2.77) 0.001
8 (0.97–0.99) 0.001 0.99 (0.98–1.00) NS
(0.99–1.00) NS 1.00 (0.99–1.00) NS
9 (0.98–0.99) 0.005 0.99 (0.98–0.99) 0.005
7 (0.62–1.22) NS 0.82 (0.58–1.16) NS
2 (0.72–1.45) NS 1.03 (0.72–1.46) NS
2 (1.01–1.98) 0.043 1.41 (1.01–1.98) 0.047
9 (0.91–1.32) NS 1.09 (0.91–1.31) NS
5 (1.23–2.21) 0.001 1.50 (1.12–2.01) 0.007
Excluded 1.38 (1.14–1.67) 0.001
201.25 227.63 0.0001*
rkers (except ProSP) that were signiﬁcant on univariable analysis. Multivariable model
ment in log likelihood chi-square for models.
TABLE 6 Cox Regression Analysis for Endpoints at 6 Months (MACE, Death and/or Reinfarction, Death and/or HF)
Univariable,
HR (95% CI) p Value
Multivariable
(ProSP Excluded),
HR (95% CI) p Value
Multivariable
(NTproBNP Excluded),
HR (95% CI) p Value
Multivariable
(ProSP and NTproBNP Included),
HR (95% CI) p Value
MACE
GRACE 1.02 (1.02–1.03) 0.0005 1.02 (1.01–1.02) 0.0005 1.02 (1.01–1.02) 0.0005 1.02 (1.01–1.02) 0.0005
NT-proBNP 2.02 (1.67–2.44) 0.0005 1.29 (1.04–1.60) 0.002 Excluded 1.29 (1.04–1.60) 0.02
ProSP 1.76 (1.57–1.96) 0.0005 Excluded 1.38 (1.18–1.61) 0.0005 1.31 (1.11–1.54) 0.001
LL chi-square 101.13 (GRACE only) 108.57 0.006* 122.84 0.0001* 126.63 0.0001*†
Death and/or reinfarction
GRACE 1.02 (1.01–1.02) 0.0005 1.02 (1.01–1.02) 0.0005 1.01 (1.01–1.02) 0.0005 1.01 (1.01–1.02) 0.0005
NT-proBNP 1.89 (1.53–2.33) 0.0005 1.38 (1.08–1.75) 0.009 Excluded 1.24 (0.98–1.57) NS
ProSP 1.70 (1.52–1.90) 0.0005 Excluded 1.47 (1.26–1.72) 0.0005 1.42 (1.21–1.67) 0.0005
LL chi-square 58.36 (GRACE only) 63.89 0.019* 85.53 0.0001* 88.42 0.0001*†
Death and/or HF
GRACE 1.03 (1.02–1.04) 0.0005 1.03 (1.02–1.03) 0.0005 1.03 (1.02–1.03) 0.0005 1.02 (1.02–1.03) 0.0005
NT-proBNP 3.22 (2.47–4.20) 0.0005 2.06 (1.50–2.82) 0.0005 Excluded 1.85 (1.34–2.55) 0.0005
ProSP 1.95 (1.74–2.19) 0.0005 Excluded 1.43 (1.19–1.71) 0.0005 1.28 (1.05–1.56) 0.01
LL chi-square 130.66 (GRACE only) 142.55 0.0001* 152.05 0.0001* 159.27 0.0001*†
LL chi-square refers to the log likelihood chi-square of the model with associated p value for added value of the biomarker(s). *Compared with GRACE only. †Compared with GRACE and NT-proBNP model.
Abbreviations as in Tables 1, 2, 3, and 5.
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clinical variables and NT-proBNP (log likelihood chi-
square test p < 0.0001 for both composite endpoints).
COMPARISON WITH GRACE SCORES
The GRACE risk score (17) was originally derived for
prediction of death and/or reinfarction at 6 months.
We investigated the utility of the biomarkers NT-
proBNP and ProSP for prediction of death and/or
reinfarction as well as other composite endpoints
(MACE, death, and/or HF). In univariate analysis,TABLE 7 Reclassiﬁcation Analysis Using Continuous Reclassiﬁcation
Outcome 6-Month Death/MI
Endpoint NRI (95% CI) p Value NRI (95
Adding NT-proBNP to GRACE
No –7.7 (–14.5 to –1.0) 0.025 –7.5 (–14.5
Yes 37.3 (21.3 to 53.3) 0.0005 33.7 (19.6
Total 29.6 (12.2 to 47.0) 0.001 26.1 (10.4
Adding ProSP to GRACE
No 22.3 (15.5 to 29.1) 0.0005 18.6 (11.6
Yes 9.3 (–6.7 to 25.3) NS 4.7 (–9.4
Total 31.6 (14.2 to 49.0) 0.0005 23.3 (7.5 t
Adding ProSP to GRACE and NT-proBNP
No 18.0 (11.2 to 24.8) 0.0005 13.6 (6.6 t
Yes 9.3 (–6.7 to 25.3) NS 2.6 (–11.5
Total 27.3 (10.0 to 44.7) 0.002 16.2 (0.4 t
Analysis shows the NRI and the signiﬁcance of the NRI, of adding NT-proBNP or ProSP to
using GRACE scoring with NT-proBNP, for the endpoints of death and/or reinfarction, M
MI ¼ myocardial infarction; NRI ¼ net reclassiﬁcation improvement; other abbreviatioGRACE scores and the biomarkers NT-proBNP and
ProSP predicted all composite endpoints (Table 6). In
multivariate analysis for MACE, death, and/or recur-
rent AMI, and death and/or HF at 6 months, both
NT-proBNP and ProSP demonstrated added value to
the GRACE score. Moreover, ProSP showed added
value to models with GRACE and NT-proBNP for all
composite endpoints analyzed (p < 0.0001 for all)
(Table 6).
Using receiver-operating characteristic curve anal-
ysis for death and/or reinfarction at 6 months, the
area under the curve (AUC) increased from 0.696-Month MACE 6-Month Death/HF
% CI) p Value NRI (95% CI) p Value
to –0.6) 0.033 7.2 (0.5 to 13.9) 0.034
to 47.8) 0.0005 37.4 (20.3 to 54.5) 0.0005
to 41.9) 0.001 44.6 (26.2 to 63.0) 0.0005
to 25.5) 0.0005 20.0 (13.4 to 26.7) 0.0005
to 18.8) NS 8.4 (–8.7 to 25.5) NS
o 39.0) 0.004 28.4 (10.1 to 46.8) 0.002
o 20.5) 0.0005 3.3 (–3.4 to 10.0) NS
to 16.7) NS 6.9 (–10.3 to 24.0) NS
o 31.9) 0.044 10.1 (–8.3 to 28.5) NS
the classiﬁcation using GRACE scoring only, and for adding ProSP to the classiﬁcation
ACE, and death and/or HF at 6 months.
ns as in Tables 1, 2, and 5.
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FIGURE 3 Classiﬁcation Tree for the Endpoint of Death
and/or Reinfarction at 6 Months
A classiﬁcation tree using plasma ProSP as the initial classiﬁer, followed by the GRACE
score or plasma NT-proBNP enables effective selection of low- and high-risk groups of
patients after acute myocardial infarction. GRACE ¼ Global Registry of Acute Coronary
Events; MI ¼ myocardial infarction; NT-proBNP ¼ N-terminal pro-B-type natriuretic
peptide; ProSP ¼ pro-substance P.
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1705(95% CI: 0.65 to 0.74) for GRACE scoring only to
0.72 (95% CI: 0.68 to 0.77) with the addition of
ProSP (p ¼ 0.01). Addition of NT-proBNP to the
GRACE score yielded a higher area (AUC: 0.70;
95% CI: 0.65 to 0.75; p ¼ NS). Comparison of the
areas for GRACE score and NT-proBNP (AUC: 0.70;
95% CI: 0.65 to 0.75) and that of GRACE score,
NT-proBNP, and ProSP (AUC: 0.72; 95% CI: 0.68 to
0.77) was not signiﬁcant (p ¼ 0.06).
RECLASSIFICATION ANALYSIS. Category-free reclassiﬁ-
cation analysis (with no arbitrary cutoff probabilities)
was employed to calculate the net reclassiﬁcation
improvement for the effect of adding NT-proBNP
or ProSP to the probabilities derived from the
GRACE score in predicting the endpoints of death
and/or reinfarction, MACE, and death and/or HF
(Table 7). NT-proBNP up-classiﬁed risk in all those
with events for all these composite endpoints. How-
ever, it wrongly (and signiﬁcantly) up-classiﬁed risk
in those without events for the death and/or rein-
farction and MACE endpoints, although it correctly
down-classiﬁed risk in those without events for
the death and/or HF endpoint. However, ProSP cor-
rectly down-classiﬁed risk in those without events
for all composite endpoints. When ProSP was added
to a composite risk score composed of GRACE and
NT-proBNP, ProSP down-classiﬁed risk in those with-
out events for the endpoints of MACE and death
and/or MI, but did not signiﬁcantly reclassify those
with the speciﬁc endpoint of death and/or HF
(Table 7).
DECISION TREE ANALYSIS. To determine optimal
cut points for biomarkers, we constructed decision
trees (using ProSP and NT-proBNP levels and GRACE
scores) to classify patients for event-free survival
or those with an endpoint of death and/or rein-
farction at 6 months. Using ProSP as an initial
classiﬁer (Figure 3), a ProSP level <72.08 pmol/l and
GRACE score <137 deﬁnes a low-risk group of pa-
tients (n ¼ 512, 44.6% of the total) who had an
event rate that was 3.0%. Of these, only 1 (0.09%)
had died within 30 days, and 3 patients (0.26%) had
died within 6 months. ProSP levels >121.6 pmol/l
deﬁned a high-risk group of patients with a death/
recurrent AMI rate of 37.7% and a death rate of
30.7% (Figure 3).
DISCUSSION
In our cohort of AMI patients, ProSP was most
strongly correlated with renal function and was
also inﬂuenced by age, past history of diabetes and
ischemic heart disease, Killip class, wall motionindex, sex, and blood pressure. There was no relation
to infarct size. ProSP may therefore closely reﬂect a
patient’s renal function at AMI presentation. ProSP
levels peaked at days 1 and 2 after chest pain onset,
permitting an early assessment of risk.
During follow-up, ProSP was associated with car-
diovascular outcomes such as death, recurrent AMI,
and HF rehospitalization. Existing biomarkers such as
NT-proBNP mainly predicted mortality and HF, with
poorer detection of death and/or reinfarction. In
contrast, ProSP provided independent prognostic in-
formation for the composite of MACE, death and/or
reinfarction, and also death and/or HF. These ana-
lyses suggest that SP may potentially have a role in
the pathophysiology of outcomes after AMI.
Analysis of the increment in receiver-operating
characteristic AUC showed that addition of ProSP had
small effects on this area. However, such analyses are
relatively insensitive to the addition of novel bio-
markers (20) and reclassiﬁcation analyses should also
be performed. For example, NT-proBNP demonstrated
a small nonsigniﬁcant increase in receiver-operating
characteristic AUC, whereas it showed added value
in reclassiﬁcation analyses for both up- and down-
classifying risk in those with MACE, death and/or
MI, and death and/or HF. In the reclassiﬁcation
analysis, ProSP demonstrated additional utility to
the GRACE score, used as a standard risk classiﬁ-
cation tool in AMI, mainly by down-classifying risk
in those without endpoints. Such a biomarker
CENTRAL ILLUSTRATION Pathophysiological Pathways Involving Substance P
After Myocardial Infarction
Substance P may affect cardiac function through effects on vasculature, platelets, clot
strength, inﬂammation, and myocardial remodeling and contractility, resulting in adverse
outcomes (death, reinfarction, and heart failure). AMI ¼ acute myocardial infarction;
NO ¼ nitric oxide.
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1706would be especially useful in detecting patients
with low risk, which was conﬁrmed on decision tree
analysis. ProSP levels <72.1 pmol/l may deﬁne a
low-risk group of patients, who potentially could be
discharged from hospital earlier. The event rates in
this group were very low during follow-up with
only 3 deaths (0.26%) by 6 months.
Reclassiﬁcation analyses also suggested that NT-
proBNP could up- or down-classify risk in those
assessed with the GRACE score, but ProSP only
showed added value for the endpoints of MACE and
death and/or MI not death and/or HF. However,
because the GRACE score was derived mainly for
prediction of death and/or MI, this could be a limi-
tation when including HF as an endpoint.
Association of ProSP with poor outcomes may
reﬂect some of the known effects of SP on physiology
and pathophysiology (Central Illustration). The asso-
ciation with HF rehospitalization could be due to the
known negative inotropic and lusitropic effects of SP
that have been demonstrated in animal models of
AMI (4,5). SP is expressed in monocytes and macro-
phages (21) and may play a role in inﬂammation (22)
as well as leukocyte chemotaxis and egress from
vessels (1,2), which may also affect myocardial func-
tion. Emerging evidence suggests SP is a mast cell
secretagogue via the NK1 receptor and mast cells may
play a role in adverse remodelling (23,24). In animal
models of remodelling from volume overload, NK1
antagonists prevented an increase in mast celldensity and myocardial tumor necrosis factor alpha
(23), and remodelling also was reduced in TAC1 gene
knockout mice. Mast cells are co-localized with car-
diac nerves (24) and secrete proteases to activate
collagenases and gelatinases, the putative media-
tors of remodelling. Furthermore, mast cells secrete
stored renin, resulting in local activation of the renin-
angiotensin system (9).
The association of SP with readmission for AMI may
be due to effects of SP on platelet aggregation (6,25).
Tachykinin family peptides (SP, endokinins A and B)
are found in platelets (25), and receptors on platelet
membranes (NK1 and NK3) may mediate a modulatory
positive paracrine feedback on platelet activation. NK1
inhibition reduces thrombus formation, but SP
strengthens a clot after formation (8), which is
dependent on NK1 receptors on leucocytes. This effect
is moremarked in those patients with a full-length NK1
receptor (8). In addition, SP may reduce tissue plas-
minogen activator activity and expression (7), hence
potentially promoting thrombosis.
On the other hand, SP also may have some poten-
tially beneﬁcial roles in ischemia post-conditioning
(26) and in mobilization of progenitor cells that may
play a role in angiogenesis within ischemic tissue (27).
Our ﬁndings are hypothesis-generating for investi-
gating the role of SP on outcomes after AMI, as it is
uncertain whether beneﬁcial effects of SP could be
outweighed by their deleterious effects.
STUDY LIMITATIONS. Our ﬁndings are on the basis of
a population from a single center, with 2 admitting
hospitals, and should be veriﬁed in other larger pop-
ulations. The rate of early revascularization in our
non-STEMI population was low and may not reﬂect
the more contemporary invasive approach of revas-
cularization within 72 h of presentation. One advan-
tage is that the relation of ProSP with poor outcomes
would not have been confounded by higher early
revascularization rates.
CONCLUSIONS
After AMI, circulating ProSP levels provide added
value to the prognostic information determined by
the GRACE score and the prognostically important
biomarker NT-proBNP. The ability of ProSP to predict
recurrent AMI in addition to mortality may confer
clinical utility on the tachykinin system in risk strat-
iﬁcation after AMI.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Pro-
substance P provides information beyond that of existing
clinical risk assessment tools and may have prognostic
value in patients with myocardial infarction as a predictor
of heart failure, reinfarction, and survival.
TRANSLATIONAL OUTLOOK 1: Larger multicenter
studies are needed to explore the value of Pro-substance P
in clinical risk stratiﬁcation among survivors of acute
coronary syndromes.
TRANSLATIONAL OUTLOOK 2: The effect of neuro-
kinin receptor inhibitors on clinical outcomes after
myocardial infarction requires further investigation.
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